Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme

Peyrin-Biroulet, Laurent; C Dubinsky, Marla; E Sands, Bruce; Panés, Julian; Schreiber, Stefan; Reinisch, Walter; G Feagan, Brian; Danese, Silvio; J Yarur, Andres; R D’Haens, Geert; Goetsch, Martina; Wosik, Karolina; Keating, Michael; Lazin, Krisztina; Wu, Joseph; Modesto, Irene; McDonnell, Aoibhinn; Bartolome, Lauren; Vermeire, Séverine

doi:10.1093/ecco-jcc/jjae038

Public

Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme

Shared by NobleBlocks on Apr 13, 2024 • 12:00 AM UTC

Authors:

Laurent Peyrin-Biroulet

Marla C Dubinsky

Bruce E Sands

Abstract

Abstract Background and Aims Pivotal trials in ulcerative colitis have historically excluded patients with isolated proctitis. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis. This post ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!